CLEC4C and CD4+/CD56+ hematodermic neoplasm: Investigations into the role of CD303 in the biology and immune regulation of BPDCN are expected to result in novel, mechanism-based therapies tailored to the unique molecular characteristics of BPDCN (Figure 3).